ANGPTL3 and metabolic syndrome: Given the crucial role ANGPTL3 plays in this process and the results of loss of function studies conducted on hypertriglyceridemia, inhibiting ANGPTL3 activity may provide a pharmacological approach for treating dyslipidemia and lowering the risk of CVD, according to research and clinical investigations on the protein.